{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T07:57:03Z","timestamp":1777535823038,"version":"3.51.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"SwanBio Therapeutics","award":["SwanBio Therapeutics"],"award-info":[{"award-number":["SwanBio Therapeutics"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adrenomyeloneuropathy (AMN) is a neurodegenerative disease phenotype of X-linked adrenoleukodystrophy (ALD), resulting in progressive myeloneuropathy causing spastic paraparesis, sensory ataxia, and bowel\/bladder symptoms. We conducted a retrospective cohort study using two large administrative databases to characterize mortality and the burden of illness in adult men with AMN in the US.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Healthcare resource use was assessed using a national commercial insurance claims database (2006\u20132021). Males with AMN ages 18\u201364 years and no evidence of cerebral ALD or other peroxisomal disorders were included and 1:4 matched on demographic characteristics to individuals without AMN. All study participants were followed for as long as observable. Patients with AMN were also identified in the Medicare Limited Dataset (2017\u20132022); mortality and age at death were compared with all Medicare enrollees. We identified 303 commercially insured men with AMN. Compared with non-AMN, individuals with AMN had significantly more inpatient hospital admissions (0.44 vs. 0.04 admissions\/patient\/year), outpatient clinic (8.88 vs. 4.1 visits\/patient\/year), outpatient hospital (5.33 vs. 0.99\u00a0visits\/patient\/year), and home healthcare visits (4.66 vs. 0.2 visits\/patient\/year), durable medical equipment claims (0.7 vs. 0.1 claims\/patient\/year), and prescription medication fills (18.1 vs. 5.4 fills\/patient\/year) (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Average length-of-stay per hospitalization was also longer in AMN (8.88 vs. 4.3 days;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Rates of comorbidities were significantly more common in AMN compared to controls, including peripheral vascular disease (4.6% vs. 0.99%), chronic pulmonary disease (6.3% vs. 2.6%), and liver disease (5.6% vs. 0.88%), all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001. Among individuals age\u2009&lt;\u200965 with Medicare disability coverage, mortality rates were 5.3x higher for adult AMN males (39.3% vs. 7.4%) and the age at death significantly younger (47.0\u2009\u00b1\u200911.3 vs. 56.5\u2009\u00b1\u20097.8 years), both\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001. Among Medicare beneficiaries ages\u2009\u2265\u200965 mortality rates were 2.2x higher for men with AMN vs. those without AMN (48.6% vs. 22.4%),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>AMN imposes a substantial and underrecognized health burden on men, with higher healthcare utilization, greater medical comorbidity, higher mortality rates, and younger age at death.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-024-03276-w","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T07:03:13Z","timestamp":1721199793000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Burden of illness and mortality in men with Adrenomyeloneuropathy: a retrospective cohort study"],"prefix":"10.1186","volume":"19","author":[{"given":"Joshua L.","family":"Bonkowsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bridget","family":"Healey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi C.","family":"Sacks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rona\u00e9","family":"McLin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4452-7690","authenticated-orcid":false,"given":"Philip L.","family":"Cyr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen K.","family":"Sawyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher D.","family":"Stephen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Eichler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,17]]},"reference":[{"issue":"4","key":"3276_CR1","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ana.101","volume":"49","author":"L Bezman","year":"2001","unstructured":"Bezman L, Moser AB, Raymond GV, Rinaldo P, Watkins PA, Smith KD, et al. Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening. Ann Neurol. 2001;49(4):512\u20137.","journal-title":"Ann Neurol"},{"issue":"1","key":"3276_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1148\/rg.2019180081","volume":"39","author":"LL Resende","year":"2019","unstructured":"Resende LL, de Paiva ARB, Kok F, da Costa Leite C, Lucato LT. Adult leukodystrophies: a step-by-step diagnostic approach. Radiographics. 2019;39(1):153\u201368.","journal-title":"Radiographics"},{"key":"3276_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1750-1172-7-51","volume":"7","author":"M Engelen","year":"2012","unstructured":"Engelen M, Kemp S, de Visser M, van Geel BM, Wanders RJ, Aubourg P, et al. X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management. Orphanet J Rare Dis. 2012;7:51.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"3276_CR4","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.gendis.2020.01.009","volume":"8","author":"YZ Zhang","year":"2021","unstructured":"Zhang YZ, Chen G, Pu W, Song Z, Tang L. Liu, Z. A novel ABCD1 G1202A mutation in a Chinese patient with pure adrenomyeloneuropathy and literature review. Genes Dis. 2021;8(5):709\u201314.","journal-title":"Genes Dis"},{"issue":"3","key":"3276_CR5","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.radcr.2018.11.007","volume":"14","author":"C Dato","year":"2019","unstructured":"Dato C, Capaldo G, Terracciano C, Napolitano F, D\u2019Amico A, Pappat\u00e0 S, et al. Late adult-onset adrenomyeloneuropathy evolving with atypical severe frontal lobe syndrome: importance of neuroimaging. Radiol Case Rep. 2019;14(3):309\u201314.","journal-title":"Radiol Case Rep"},{"issue":"9","key":"3276_CR6","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.bbadis.2012.03.012","volume":"1822","author":"S Kemp","year":"2012","unstructured":"Kemp S, Berger J, Aubourg P. X-linked adrenoleukodystrophy: clinical, metabolic, genetic and pathophysiological aspects. Biochim Biophys Acta. 2012;1822(9):1465\u201374.","journal-title":"Biochim Biophys Acta"},{"issue":"17","key":"3276_CR7","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","volume":"377","author":"F Eichler","year":"2017","unstructured":"Eichler F, Duncan C, Musolino PL, Orchard PJ, De Oliveira S, Thrasher AJ, et al. Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. N Engl J Med. 2017;377(17):1630\u20138.","journal-title":"N Engl J Med"},{"key":"3276_CR8","doi-asserted-by":"publisher","first-page":"7638675","DOI":"10.1155\/2019\/7638675","volume":"2019","author":"JP Antczak","year":"2019","unstructured":"Antczak JP, D\u0105bro\u015b J, Ko\u017ami\u0144ski M, Czy\u017cycki W, W\u0119\u017cyk M, Dwojak K, Banach M. Slowik, A. The Effect of Repetitive Transcranial Magnetic Stimulation on motor symptoms in Hereditary Spastic Paraplegia. Neural Plast. 2019;2019:7638675.","journal-title":"Neural Plast"},{"issue":"6 Pt 2","key":"3276_CR9","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1097\/01.ju.0000110885.26017.b0","volume":"171","author":"M Silveri","year":"2004","unstructured":"Silveri M, De Gennaro M, Gatti C, Bizzarri C, Mosiello G, Cappa M. Voiding dysfunction in x-linked adrenoleukodystrophy: symptom score and urodynamic findings. J Urol. 2004;171(6 Pt 2):2651\u20133.","journal-title":"J Urol"},{"issue":"4","key":"3276_CR10","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/pds.4165","volume":"26","author":"MS Cepeda","year":"2017","unstructured":"Cepeda MS, Fife D, Denarie M, Bradford D, Roy S, Yuan Y. Quantification of missing prescriptions in commercial claims databases: results of a cohort study. Pharmacoepidemiol Drug Saf. 2017;26(4):386\u201392.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3276_CR11","unstructured":"Services CfMM. Limited Data Set (LDS) Files 2022 [updated 07\/07\/2022. https:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Files-for-Order\/Data-Disclosures-Data-Agreements\/DUA_-_NewLDS."},{"key":"3276_CR12","unstructured":"Stephanie Jarosek P. BSN. Death Information in the Research Identifiable Medicare Data 2022 [ https:\/\/resdac.org\/articles\/death-information-research-identifiable-medicare-data."},{"issue":"6","key":"3276_CR13","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676\u201382.","journal-title":"Am J Epidemiol"},{"issue":"5","key":"3276_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"issue":"17","key":"3276_CR15","doi-asserted-by":"publisher","first-page":"644","DOI":"10.15585\/mmwr.mm7017e3","volume":"70","author":"AC Hernandez-Romieu","year":"2021","unstructured":"Hernandez-Romieu AC, Leung S, Mbanya A, Jackson BR, Cope JR, Bushman D, et al. Health Care utilization and clinical characteristics of nonhospitalized adults in an Integrated Health Care System 28\u2013180 days after COVID-19 diagnosis - Georgia, May 2020-March 2021. MMWR Morb Mortal Wkly Rep. 2021;70(17):644\u201350.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"3276_CR16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3389\/fphar.2013.00066","volume":"4","author":"B Polek","year":"2013","unstructured":"Polek B, Roach MJ, Andrews WT, Ehling M, Salek S. Burden of Friedreich\u2019s Ataxia to the patients and Healthcare Systems in the United States and Canada. Front Pharmacol. 2013;4:66.","journal-title":"Front Pharmacol"},{"issue":"18","key":"3276_CR17","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1212\/WNL.0000000000201436","volume":"99","author":"BF Bebo","year":"2022","unstructured":"Bebo BF. Author response: the Economic Burden of multiple sclerosis in the United States: Estimate of Direct and Indirect costs. Neurology. 2022;99(18):819.","journal-title":"Neurology"},{"issue":"1","key":"3276_CR18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13023-020-01596-1","volume":"16","author":"CS Corre","year":"2021","unstructured":"Corre CS, Grant N, Sadjadi R, Hayden D, Becker C, Gomery P, et al. Beyond gait and balance: urinary and bowel dysfunction in X-linked adrenoleukodystrophy. Orphanet J Rare Dis. 2021;16(1):14.","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"3276_CR19","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/nrendo.2016.90","volume":"12","author":"S Kemp","year":"2016","unstructured":"Kemp S, Huffnagel IC, Linthorst GE, Wanders RJ, Engelen M. Adrenoleukodystrophy - neuroendocrine pathogenesis and redefinition of natural history. Nat Rev Endocrinol. 2016;12(10):606\u201315.","journal-title":"Nat Rev Endocrinol"},{"issue":"2\u20133","key":"3276_CR20","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1159\/000490248","volume":"18","author":"Y Qiu","year":"2018","unstructured":"Qiu Y, Xin L, Wang Y, Yu Y, Zou K, Zhou Q, et al. Novel ABCD1 gene mutation in Adrenomyeloneuropathy with Hypoplasia and Agenesis of the Corpus Callosum. Neurodegener Dis. 2018;18(2\u20133):156\u201364.","journal-title":"Neurodegener Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03276-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-024-03276-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03276-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T07:08:36Z","timestamp":1721200116000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-024-03276-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,17]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3276"],"URL":"https:\/\/doi.org\/10.1186\/s13023-024-03276-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3822769\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,17]]},"assertion":[{"value":"3 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was not required as no individual\u2019s data in any form appears in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BH, NCS, RM, and PC are or where employees of a consulting firm that received funding from a pharmaceutical company for this study. ES is an employee of the pharmaceutical company. JL, CDS, and FE received honoraria for their participation in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"270"}}